Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Medical College of Wisconsin
60 participants
Jan 1, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.
Eligibility
Inclusion Criteria2
- Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
- Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor
Exclusion Criteria21
- Uncontrolled hypertension
- Current Tobacco use or within last 6 months
- BMI \> 35
- Hyperlipidemia
- Hypercholesterolemia
- Type 1 Diabetes
- Use of anti-coagulant drugs, or anti-platelet drugs
- Symptomatic coronary artery disease
- Heart Failure
- Renal Impairment
- Hormone Replacement Therapy
- History of Retinopathy
- Documented Neuromuscular Disorders
- Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
- Pregnancy (Young Female subjects)
- Allergies to Povidone Iodine
- Use Erectile Dysfunction Medication in the past 6 months
- Use of Topical/non-topical Steroids in last 6 months
- Active Anti-Cancer Treatment or Treatment within last 12 months
- Active COVID-19 or within the past 3 months
- Gender Reassignment Therapy
Interventions
Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05593549